Polycomb group protein Bmi1 is required for growth of RAF driven non-small-cell lung cancer

PLoS ONE

Volumn 4, Issue 1, 2009, Pages

  Becker, Matthias ^a   Korn, Christian ^a   Sienerth, Arnold R ^a   Voswinckel, Robert ^b   Luetkenhaus, Katharina ^a   Ceteci, Faith ^a   Rapp, Ulf R ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BMI1 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2D; RAF PROTEIN; BMI1 PROTEIN, MOUSE; NUCLEAR PROTEIN; ONCOPROTEIN; REPRESSOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INCIDENCE; CELL CYCLE PROGRESSION; CELL DEATH; CONTROLLED STUDY; ENZYME REGULATION; LIFESPAN; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TUMOR VOLUME; UPREGULATION; ANIMAL; BIOLOGICAL MODEL; C57BL MOUSE; CELL TRANSFORMATION; CROSS BREEDING; GENE EXPRESSION REGULATION; GENETICS; LUNG; LUNG TUMOR; METABOLISM; PHYSIOLOGY; TRANSGENIC MOUSE;

MUS; MUS MUSCULUS;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL TRANSFORMATION, NEOPLASTIC; CROSSES, GENETIC; CYCLIN-DEPENDENT KINASE INHIBITOR P16; GENE EXPRESSION REGULATION, NEOPLASTIC; LUNG; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MODELS, GENETIC; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; RAF KINASES; REPRESSOR PROTEINS; TUMOR SUPPRESSOR PROTEIN P14ARF;

EID: 64149118533     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0004230     Document Type: Article

References (38)

1. Marks JL, McLellan MD, Zakowski MF, Lash AE, Kasai Y, et al. (2007) Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4. PLoS ONE 2: e426.
2. Meuwissen R, Linn SC, Linnoila RI, Zevenhoven J, Mooi WJ, et al. (2003) Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell 4: 181-189.
3. Meuwissen R, Linn SC, van der Valk M, Mooi WJ, Berns A (2001) Mouse model for lung tumorigenesis through Cre/lox controlled sporadic activation of the K-Ras oncogene. Oncogene 20: 6551-6558.
4. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, et al. (2001) Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 15: 3243-3248.
5. Dankort D, Filenova E, Collado M, Serrano M, Jones K, et al. (2007) A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev 21: 379-384.
6. Fisher GH, Wellen SL, Klimstra D, Lenczowski JM, Tichelaar JW, et al. (2001) Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev 15: 3249-3262.
7. Kerkhoff E, Fedorov LM, Siefken R, Walter AO, Papadopoulos T, et al. (2000) Lung-targeted expression of the c-Raf-1 kinase in transgenic mice exposes a novel oncogenic character of the wild-type protein. Cell Growth Differ 11: 185-190.
8. Ceteci F, Ceteci S, Karreman C, Kramer BW, Asan E, et al. (2007) Disruption of tumor cell adhesion promotes angiogenic switch and progression to micrometastasis in RAF-driven murine lung cancer. Cancer Cell 12: 145-159.
9. Fedorov LM, Papadopoulos T, Tyrsin OY, Twardzik T, Gotz R, et al. (2003) Loss of p53 in craf-induced transgenic lung adenoma leads to tumor acceleration and phenotypic switch. Cancer Res 63: 2268-2277.
10. Fedorov LM, Tyrsin OY, Papadopoulos T, Camarero G, Gotz R, et al. (2002) Bcl-2 determines susceptibility to induction of lung cancer by oncogenic CRaf. Cancer Res 62: 6297-6303.
11. Gotz R, Kramer BW, Camarero G, Rapp UR (2004) BAG-1 haplo-insufficiency impairs lung tumorigenesis. BMC Cancer 4: 85.
12. Kramer BW, Gotz R, Rapp UR (2004) Use of mitogenic cascade blockers for treatment of C-Raf induced lung adenoma in vivo: CI-1040 strongly reduces growth and improves lung structure. BMC Cancer 4: 24.
13. Yamanaka Y, Ralston A, Stephenson RO, Rossant J (2006) Cell and molecular regulation of the mouse blastocyst. Dev Dyn 235: 2301-2314.
14. Sangiorgi E, Capecchi MR (2008) Bmi1 is expressed in vivo in intestinal stem cells. Nat Genet 40: 915-920.
15. Sparmann A, van Lohuizen M (2006) Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 6: 846-856.
16. Breuer RH, Snijders PJ, Smit EF, Sutedja TG, Sewalt RG, et al. (2004) Increased expression of the EZH2 polycomb group gene in BMI-1-positive neoplastic cells during bronchial carcinogenesis. Neoplasia 6: 736-743.
17. Vrzalikova K, Skarda J, Ehrmann J, Murray PG, Fridman E, et al. (2008) Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study. J Cancer Res Clin Oncol.
18. Glinsky GV, Berezovska O, Glinskii AB (2005) Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 115: 1503-1521.
19. Voncken JW, Niessen H, Neufeld B, Rennefahrt U, Dahlmans V, et al. (2005) MAPKAP kinase 3pK phosphorylates and regulates chromatin association of the polycomb group protein Bmi1. J Biol Chem 280: 5178-5187.
20. Voswinckel R, Motejl V, Fehrenbach A, Wegmann M, Mehling T, et al. (2004) Characterisation of post-pneumonectomy lung growth in adult mice. Eur Respir J 24: 524-532.
21. Roper JM, Staversky RJ, Finkelstein JN, Keng PC, O'Reilly MA (2003) Identification and isolation of mouse type II cells on the basis of intrinsic expression of enhanced green fluorescent protein. Am J Physiol Lung Cell Mol Physiol 285: L691-700.
22. Lobo NA, Shimono Y, Qian D, Clarke MF (2007) The biology of cancer stem cells. Annu Rev Cell Dev Biol 23: 675-699.
23. Valk-Lingbeek ME, Bruggeman SW, van Lohuizen M (2004) Stem cells and cancer; the polycomb connection. Cell 118: 409-418.
24. Alkema MJ, van der Lugt NM, Bobeldijk RC, Berns A, van Lohuizen M (1995) Transformation of axial skeleton due to overexpression of bmi-1 in transgenic mice. Nature 374: 724-727.
25. Liu L, Andrews LG, Tollefsbol TO (2006) Loss of the human polycomb group protein BMI1 promotes cancer-specific cell death. Oncogene 25: 4370-4375.
26. Yu Q, Su B, Liu D, Liu B, Fan Y, et al. (2007) Antisense RNA-mediated suppression of Bmi-1 gene expression inhibits the proliferation of lung cancer cell line A549. Oligonucleotides 17: 327-335.
27. Pardal R, Molofsky AV, He S, Morrison SJ (2005) Stem cell self-renewal and cancer cell proliferation are regulated by common networks that balance the activation of proto-oncogenes and tumor suppressors. Cold Spring Harb Symp Quant Biol 70: 177-185.
28. Zhuang D, Mannava S, Grachtchouk V, Tang WH, Patil S, et al. (2008) C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells. Oncogene 27: 6623-6634.
29. Bruggeman SW, Hulsman D, Tanger E, Buckle T, Blom M, et al. (2007) Bmi1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma. Cancer Cell 12: 328-341.
30. Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, et al. (1998) The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92: 713-723.
31. Zhang Y, Xiong Y, Yarbrough WG (1998) ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92: 725-734.
32. Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, et al. (1997) Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91: 649-659.
33. de Stanchina E, McCurrach ME, Zindy F, Shieh SY, Ferbeyre G, et al. (1998) E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev 12: 2434-2442.
34. Palmero I, Pantoja C, Serrano M (1998) p19ARF links the tumour suppressor p53 to Ras. Nature 395: 125-126.
35. Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, et al. (1998) Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 12: 2424-2433.
36. Lee C, Smith BA, Bandyopadhyay K, Gjerset RA (2005) DNA damage disrupts the p14ARF-B23(nucleophosmin) interaction and triggers a transient subnuclear redistribution of p14ARF. Cancer Res 65: 9834-9842.
37. Menges CW, McCance DJ (2008) Constitutive activation of the Raf-MAPK pathway causes negative feedback inhibition of Ras-PI3K-AKT and cellular arrest through the EphA2 receptor. Oncogene 27: 2934-2940.
38. Dovey JS, Zacharek SJ, Kim CF, Lees JA (2008) Bmi1 is critical for lung tumorigenesis and bronchioalveolar stem cell expansion. Proc Natl Acad Sci U S A 105: 11857-11862.